93. Primary biliary cholangitis Disease details / Clinical trials / Drug dev / DR info

1-20190   
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria;
11C-CSar   
   University of Aarhus
      2013   Phase 1   NCT01879735   Denmark;
13-15mg/kg/d Ursodeoxycholic   
   West China Hospital
      2018   Phase 4   NCT03345589   China;
18-22mg/kg/d Ursodeoxycholic   
   West China Hospital
      2018   Phase 4   NCT03345589   China;
3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2021   Phase 3   EUCTR2021-000007-21-IT   Argentina;Belgium;Canada;China;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;United Kingdom;United States;
3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom;
3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom;
6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747   
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA)   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA)   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA)   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom;
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA)   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom;
A11HA02   
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom;
A4250   
   Albireo
      2013   Phase 1   NCT02963077   -
   Sahlgrenska Academy
      2014   Phase 2   EUCTR2014-004070-42-SE   Sweden;
   Sahlgrenska University Hospital, Sweden
      2015   Phase 2   NCT02360852   Sweden;
APD334   
   Arena Pharmaceuticals
      2017   Phase 2   NCT03155932   Australia;New Zealand;United States;
ASC42   
   Gannex Pharma Co., Ltd.
      2022   Phase 2   NCT05190523   -
Abatacept   
   Christopher Bowlus, MD
      2014   Phase 4   NCT02078882   United States;
Acido Obeticolico   
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Acido ursodessicolico   
   DR. FALK PHARMA GMBH
      2009   Phase 3   EUCTR2007-004040-70-IT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
Alkaline Phosphatase   
   You'an Hospital, Capital Medical University
      2020   -   ChiCTR2000032053   China;
Atorvastatin   
   Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology
      2005   -   EUCTR2005-002160-28-AT   Austria;
   Medical University of Graz
      2006   Phase 3   NCT00844402   Austria;
BCD-085   
   Biocad
      2018   Phase 2   NCT03476993   Russian Federation;
Baricitinib   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 2   EUCTR2018-003365-34-IT   Italy;United Kingdom;United States;
   Eli Lilly and Company
      2019   Phase 2   NCT03742973   Italy;Puerto Rico;United Kingdom;United States;
Bezafibrat Genericon retard   
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria;
Bezafibrate   
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2016   Phase 3   NCT02701166   Netherlands;Spain;
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01654731   France;
   Gunma Liver Study Group
      2003   -   JPRN-C000000225   Japan;
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2016   Phase 3   NCT02937012   Mexico;
   Intercept Pharmaceuticals
      2022   Phase 2   NCT05239468   United States;
      2019   Phase 2   NCT04594694   Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;
   Shinshu University Faculty of Medicine, Department of Gastroenterology
      2020   -   JPRN-UMIN000039350   Japan;
Bezafibrate 200 MG Oral Tablet   
   Instituto Mexicano del Seguro Social
      2020   Phase 3   NCT04751188   Mexico;
Bezafibrate IR   
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
Bezafibrate SR   
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
Bezafibrate, Beza, BZF, Bezalip   
   Intercept Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
Bezafibrate, Beza, BZF, Bezalip mono   
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
Bezalip   
   Academic Medical Center
      2017   Phase 2   EUCTR2014-001438-27-ES   Netherlands;Spain;
      2015   -   EUCTR2014-001438-27-NL   Netherlands;
Bezalip mono   
   Intercept Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
Budenofalk   
   Dr. Falk Pharma GmbH
      2013   -   EUCTR2007-004040-70-PL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004040-70-GB   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2007-004040-70-DK   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2007-004040-70-AT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-004040-70-SE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-004040-70-ES   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-NL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-LT   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-HU   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-FR   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-FI   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-DE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
Budesonide   
   DR. FALK PHARMA GMBH
      2009   Phase 3   EUCTR2007-004040-70-IT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
   Dr. Falk Pharma GmbH
      2009   Phase 3   NCT00746486   France;Germany;
   Mayo Clinic
      2007   -   NCT00587119   United States;
CNP-104   
   COUR Pharmaceutical Development Company, Inc.
      2022   Phase 1/Phase 2   NCT05104853   United States;
CNTO1275   
   Janssen-Cilag International N.V.
      2011   Phase 2   EUCTR2011-000554-31-GB   Canada;France;Germany;Italy;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000554-31-SE   Canada;France;Germany;Italy;Sweden;United Kingdom;United States;
CR845   
   Cara Therapeutics, Inc.
      2019   Phase 2   NCT03995212   United States;
CRC (A3384)   
   Albireo
      2013   Phase 1   NCT02963077   -
Calcium   
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012489   Japan;
      2013   -   JPRN-UMIN000012193   Japan;
Cilofexor   
   Gilead Sciences
      2016   Phase 2   NCT02943447   Austria;Canada;United Kingdom;United States;
Colchicine   
   National Center for Research Resources (NCRR)
      1989   Phase 3   NCT00004748   -
Combination antiviral therapy   
   University of Alberta
      2004   Phase 2/Phase 3   NCT00490620   Canada;United Kingdom;United States;
Cyclophosphamide   
   Traslational Research and Clinical Trial Center
      2012   Phase 1,2   JPRN-UMIN000015789   Japan;
Cyclosporin A   
   West China Hospital
      2021   Phase 4   NCT04376528   China;
Denosumab   
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012489   Japan;
      2013   -   JPRN-UMIN000012193   Japan;
   Tokai University School of Medicine
      2018   -   JPRN-UMIN000031384   Japan;
E6011   
   EA Pharma Co., Ltd.
      2017   Phase 2   NCT03092765   Japan;
EDP-305   
   Enanta Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2017-003528-62-BE   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003528-62-NL   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003528-62-GB   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003528-62-ES   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003528-62-DE   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003528-62-AT   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
EDP-305 Dose 1   
   Enanta Pharmaceuticals
      2017   Phase 2   NCT03394924   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
EDP-305 Dose 2   
   Enanta Pharmaceuticals
      2017   Phase 2   NCT03394924   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
EZT   
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom;
Elafibranor   
   GENFIT
      2021   Phase 3   EUCTR2019-004941-34-IT   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Genfit
      2020   Phase 3   NCT04526665   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 2   NCT03124108   France;Germany;Spain;United Kingdom;United States;
   Genfit SA
      2018   Phase 2   EUCTR2016-003817-80-FR   France;Germany;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003817-80-GB   France;Germany;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003817-80-ES   France;Germany;Spain;United Kingdom;United States;
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)   
   University of Alberta
      2020   Phase 2   NCT03954327   Canada;
Experimental: Seladelpar / MBX-8025   
   CymaBay Therapeutics, Inc.
      2015   Phase 2   NCT02609048   Canada;Germany;Poland;United Kingdom;United States;
Ezetrol   
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom;
FFP104   
   Fast Forward Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02193360   Netherlands;United Kingdom;
   Fast Forward Pharmaceuticals, B.V.
      2015   Phase 2   EUCTR2014-001638-27-GB   Netherlands;United Kingdom;
      2014   Phase 2   EUCTR2014-001638-27-NL   Netherlands;United Kingdom;
Fenofibrate   
   Beijing 302 Hospital
      2016   Phase 1/Phase 2   NCT02965911   China;
   Peking Union Medical College Hosipital
      2018   -   ChiCTR1800020160   China;
   University of Miami
      2011   Phase 2   NCT01141296   United States;
   Xijing Hospital of Digestive Diseases
      2016   Phase 3   NCT02823366   China;
      2016   Phase 3   NCT02823353   China;
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)   
   University of Florida
      2007   Phase 2   NCT00575042   United States;
Fibroscan   
   University of Aarhus
      2016   -   NCT02931513   Denmark;
Fully human monoclonal antibody directed against CXCL10   
   NovImmune S.A.
      2011   -   EUCTR2011-001326-26-GB   Italy;United Kingdom;
Fuzhenghuayu   
   Xijing Hospital of Digestive Diseases
      2016   Phase 3   NCT02916641   China;
      2016   Phase 3   NCT02916290   China;
GFT505   
   GENFIT
      2021   Phase 3   EUCTR2019-004941-34-IT   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004941-34-FR   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004941-34-BE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Genfit SA
      2018   Phase 2   EUCTR2016-003817-80-FR   France;Germany;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003817-80-GB   France;Germany;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003817-80-ES   France;Germany;Spain;United Kingdom;United States;
GKT137831   
   GENKYOTEX SA
      2018   Phase 2   EUCTR2016-004599-23-IT   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
   Genkyotex SA
      2017   Phase 2   NCT03226067   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004599-23-GR   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004599-23-GB   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004599-23-ES   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004599-23-DE   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004599-23-BE   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States;
   Genkyotex Suisse SA
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-IT   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
GS-9674   
   Gilead Sciences, Inc.
      2017   Phase 2   EUCTR2016-002443-42-GB   Austria;Canada;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002443-42-AT   Austria;Canada;United Kingdom;United States;
GSK2330672   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2021   Phase 3   EUCTR2021-000007-21-IT   Argentina;Belgium;Canada;China;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002416-41-IT   Australia;Canada;France;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
   GlaxoSmithKline
      2017   Phase 2   NCT02966834   Australia;Canada;France;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States;
      2014   Phase 2   NCT01899703   United Kingdom;
   GlaxoSmithKline Research & Development Ltd
      2017   Phase 2   EUCTR2016-002416-41-PL   Australia;Canada;France;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002416-41-GB   Australia;Canada;France;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
   GlaxoSmithKline, S.A.
      2017   Phase 2   EUCTR2016-002416-41-ES   Australia;Canada;France;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
GYPP-06 (GKT137831 free base), C10071301-D   
   Genkyotex Suisse SA
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-PL   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-ES   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-DE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-HU   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-GR   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Gold   
   Beijing You'an Hospital, Capital Medical University
      2019   Phase 0   ChiCTR1900024836   China;
   The Second Affiliated Hospital of Kunming Medical University
      2020   -   ChiCTR2000040593   China;
   You'an Hospital, Capital Medical University
      2020   -   ChiCTR2000032053   China;
HTD1801 (BUDCA)   
   HighTide Biopharma Pty Ltd
      2021   Phase 2   NCT04604652   United States;
High protein high fiber diet   
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2011   -   NCT01603199   Mexico;
ICG   
   University of Aarhus
      2013   Phase 1   NCT01879735   Denmark;
INT-747   
   Intercept Pharmaceuticals
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom;
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2007   Phase 2   NCT00570765   Austria;Canada;France;Germany;Spain;United Kingdom;United States;
      2007   Phase 2   NCT00550862   Austria;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
INT-747, OCA   
   INTERCEPT PHARMACEUTICALS INC.
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
LJN452   
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-001590-41-PL   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States;
LJN452, 0,   
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2015-001590-41-DE   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States;
LUM001   
   Lumena Pharmaceuticals, Inc.
      2013   -   EUCTR2013-000482-36-GB   United Kingdom;United States;
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   NCT02321306   United Kingdom;United States;
      2013   Phase 2   NCT01904058   Canada;United Kingdom;United States;
LY3009104   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 2   EUCTR2018-003365-34-IT   Italy;United Kingdom;United States;
   Eli Lilly and Company
      2019   Phase 2   EUCTR2018-003365-34-GB   Italy;United Kingdom;United States;
Linerixibat   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2021   Phase 3   EUCTR2021-000007-21-IT   Argentina;Belgium;Canada;China;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;United Kingdom;United States;
   GlaxoSmithKline
      2021   Phase 3   NCT04950127   Argentina;Belgium;Canada;China;France;Germany;Italy;Japan;Mexico;Poland;Russian Federation;United Kingdom;United States;
      2020   Phase 3   NCT04167358   Canada;France;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States;
Linerixibat (GSK2330672)   
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2020   Phase 3   EUCTR2019-003158-10-IT   Canada;France;Italy;Japan;Poland;United Kingdom;United States;
   GlaxoSmithKline Research & Development Ltd
      2021   Phase 3   EUCTR2019-003158-10-FR   Canada;France;Japan;Poland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003158-10-PL   Canada;France;Italy;Japan;Poland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003158-10-GB   Canada;Japan;Poland;United Kingdom;United States;
Liver biopsy   
   University of Aarhus
      2016   -   NCT02931513   Denmark;
MBX 8025   
   CymaBay Therapeutics Inc.
      2016   Phase 2   EUCTR2015-002698-39-PL   Canada;Germany;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002698-39-GB   Canada;Germany;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002698-39-DE   Canada;Germany;Poland;United Kingdom;United States;
MBX-8025   
   CymaBay Therapeutics Inc.
      2016   Phase 2   EUCTR2015-002698-39-PL   Canada;Germany;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002698-39-GB   Canada;Germany;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002698-39-DE   Canada;Germany;Poland;United Kingdom;United States;
   CymaBay Therapeutics, Inc.
      2022   Phase 3   EUCTR2020-004348-27-DK   Argentina;Australia;Austria;Belgium;Canada;Chile;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-NL   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-IT   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-HU   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-DE   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005198-29-PL   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004348-27-PL   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004348-27-NL   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004348-27-IT   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004348-27-HU   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004348-27-DE   Argentina;Australia;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001171-20-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001171-20-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001171-20-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001171-20-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001171-20-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001171-20-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001171-20-HU   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001171-20-GR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001171-20-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001171-20-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-003910-16-DE   Canada;Germany;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002996-91-GB   Canada;Germany;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002996-91-DE   Canada;Germany;United Kingdom;United States;
      -   Phase 3;Phase 4   EUCTR2020-005198-29-FR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
MBX-8025 10 mg Capsule   
   CymaBay Therapeutics, Inc.
      2016   Phase 2   NCT02955602   Canada;Germany;United Kingdom;United States;
MBX-8025 2 mg Capsule   
   CymaBay Therapeutics, Inc.
      2016   Phase 2   NCT02955602   Canada;Germany;United Kingdom;United States;
MBX-8025 5 mg Capsule   
   CymaBay Therapeutics, Inc.
      2016   Phase 2   NCT02955602   Canada;Germany;United Kingdom;United States;
MBX-8025, DSIC   
   CymaBay Therapeutics, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-003910-16-GB   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
MBX-8025, Formulation 2   
   CymaBay Therapeutics, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-003910-16-GB   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
MXB-8025   
   CymaBay Therapeutics, Inc.
      2018   Phase 3   EUCTR2018-001171-20-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
MabThera®   
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 2   EUCTR2012-000145-12-GB   United Kingdom;
Methotrexate   
   National Center for Research Resources (NCRR)
      1994   Phase 3   NCT00004784   -
      1989   Phase 3   NCT00004748   -
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1994   Phase 3   NCT00006168   United States;
Methylprednisolone and Mycophenolate mofetil   
   Xiaoli Fan
      2021   Phase 4   NCT04933292   China;
Methylprednisolone and azathioprine   
   Xiaoli Fan
      2021   Phase 4   NCT04933292   China;
Minodronic acid   
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012193   Japan;
Modafinil   
   Mayo Clinic
      2009   Phase 1   NCT00943176   United States;
Moexipril   
   Mayo Clinic
      2003   Phase 2   NCT00588302   United States;
NGM282   
   NGM Biopharmaceuticals, Inc
      2014   Phase 2   NCT02135536   Australia;New Zealand;United States;
      2014   Phase 2   NCT02026401   Australia;United States;
NI-0801   
   NOVIMMUNE BV
      2011   -   EUCTR2011-001326-26-IT   Italy;
   NovImmune S.A.
      2011   -   EUCTR2011-001326-26-GB   Italy;United Kingdom;
   NovImmune SA
      2011   Phase 2   NCT01430429   Italy;United Kingdom;
Non-myeloablative Hematopoietic Stem Cell Transplantation   
   Richard Burt, MD
      2006   Phase 1   NCT00393185   United States;
Norucholic acid (NCA)   
   Dr. Falk Pharma GmbH
      2022   Phase 2   EUCTR2021-001431-56-DE   Austria;Belgium;Denmark;Finland;France;Germany;Lithuania;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;
OCA (INT-747)   
   AMC
      2017   Phase 2   EUCTR2016-002965-67-NL   Netherlands;
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Intercept Pharmaceuticals, Inc.
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-NL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
OP-724   
   Kiminori Kimura, MD
      2019   Phase 1   NCT04047160   Japan;
Obeticholic Acid (OCA)   
   Intercept Pharmaceuticals
      2018   Phase 4   NCT03633227   Argentina;Australia;Belgium;Brazil;Canada;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United States;
      2014   Phase 4   NCT02308111   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   NCT01473524   Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Obeticholic Acid Tablets   
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2021   Phase 3   NCT04956328   China;
Obeticholic acid   
   Intercept Pharmaceuticals
      2019   Phase 2   NCT04594694   Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom;
   Intercept Pharmaceuticals, Inc.
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-NL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   University of Aarhus
      2016   Early Phase 1   NCT03253276   Denmark;
Obeticholic acid (OCA)   
   Intercept Pharmaceuticals
      2013   Phase 2   NCT01865812   United States;
Ocaliva   
   INTERCEPT PHARMACEUTICALS INC.
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
   Intercept Pharmaceuticals Inc.
      2018   Phase 4   EUCTR2014-005012-42-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 4   EUCTR2014-005012-42-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 4   EUCTR2014-005012-42-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 4   EUCTR2014-005012-42-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 4   EUCTR2014-005012-42-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 4   EUCTR2014-005012-42-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   University of Leipzig
      2019   -   NCT04076527   Germany;
Olumiant   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 2   EUCTR2018-003365-34-IT   Italy;United Kingdom;United States;
   Eli Lilly and Company
      2019   Phase 2   EUCTR2018-003365-34-GB   Italy;United Kingdom;United States;
Part 1: LJN452   
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02516605   Canada;Germany;Poland;Russian Federation;United Kingdom;United States;
Part 2: LJN452 Dose level 1   
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02516605   Canada;Germany;Poland;Russian Federation;United Kingdom;United States;
Part 2: LJN452 Dose level 2   
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02516605   Canada;Germany;Poland;Russian Federation;United Kingdom;United States;
Pemafibrate   
   Kowa Co., Ltd.
      2017   Phase 1   JPRN-JapicCTI-173728   Japan;
   Shinshu University Faculty of Medicine, Department of Gastroenterology
      2020   -   JPRN-UMIN000039350   Japan;
Pentoxifylline   
   The Cleveland Clinic
      2010   Phase 2   NCT01249092   United States;
Phenylbutyrate   
   Juntendo University
      2014   -   JPRN-UMIN000012782   Japan;
   Saiseikai Yokohama City Tobu Hospital
      2010   -   JPRN-UMIN000003802   Japan;
Probiotic   
   Sun Yat-sen University
      2020   Phase 2   NCT03521297   China;
Pyridoxine 10mg BP   
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom;
Questran   
   Albireo
      2013   Phase 1   NCT02963077   -
Raltegravir   
   University of Alberta
      2020   Phase 2   NCT03954327   Canada;
RhuDex 100 mg (127 mg RhuDex choline salt) granules   
   DR. FALK PHARMA GMBH
      2021   Phase 2   EUCTR2020-001961-34-IT   Belgium;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
   Dr. Falk Pharma GmbH
      2021   Phase 2   EUCTR2020-001961-34-SK   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-001961-34-PL   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-001961-34-DE   Belgium;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;United Kingdom;
      2020   Phase 2   EUCTR2020-001961-34-NL   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom;
      2020   Phase 2   EUCTR2020-001961-34-HU   Hungary;
      2020   Phase 2   EUCTR2020-001961-34-BE   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom;
RhuDex 25 mg (31.75 mg RhuDex choline salt) granules   
   DR. FALK PHARMA GMBH
      2021   Phase 2   EUCTR2020-001961-34-IT   Belgium;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
   Dr. Falk Pharma GmbH
      2021   Phase 2   EUCTR2020-001961-34-SK   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-001961-34-PL   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-001961-34-DE   Belgium;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;United Kingdom;
      2020   Phase 2   EUCTR2020-001961-34-NL   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom;
      2020   Phase 2   EUCTR2020-001961-34-HU   Hungary;
      2020   Phase 2   EUCTR2020-001961-34-BE   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom;
RhuDex 50 mg (63.5 mg RhuDex choline salt) granules   
   DR. FALK PHARMA GMBH
      2021   Phase 2   EUCTR2020-001961-34-IT   Belgium;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
   Dr. Falk Pharma GmbH
      2021   Phase 2   EUCTR2020-001961-34-SK   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-001961-34-PL   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-001961-34-DE   Belgium;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;United Kingdom;
      2020   Phase 2   EUCTR2020-001961-34-NL   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom;
      2020   Phase 2   EUCTR2020-001961-34-HU   Hungary;
      2020   Phase 2   EUCTR2020-001961-34-BE   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom;
Rifampicin   
   The University Of Adelaide
      2020   Phase 3   EUCTR2018-004011-44-GB   Australia;Finland;Netherlands;Sweden;United Kingdom;
   The University of Adelaide
      2020   Phase 4   EUCTR2018-004011-44-FI   Australia;Finland;Netherlands;Sweden;United Kingdom;
Rifaximin   
   Xiangya Hospital of Central South University
      2021   -   ChiCTR2100046346   China;
Risedronic acid   
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012193   Japan;
Rituximab   
   Newcastle-upon-Tyne Hospitals NHS Trust
      2012   Phase 2   NCT02376335   United Kingdom;
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 2   EUCTR2012-000145-12-GB   United Kingdom;
   University of California, Davis
      2007   Phase 1/Phase 2   NCT00364819   United States;
S-adenosyl-L-methionine   
   Pomeranian Medical University Szczecin
      2015   Phase 4   NCT02557360   Poland;
S-adenosyl-methionine (SAMe) capsules   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   Phase 2   NCT00125281   United States;
Saroglitazar Magnesium   
   Zydus Therapeutics Inc.
      2022   Phase 2/Phase 3   NCT05133336   -
Saroglitazar magnesium   
   Zydus Discovery DMCC
      2017   Phase 2   NCT03112681   United States;
Seladelpar   
   CymaBay Therapeutics, Inc.
      2021   Phase 3   NCT04620733   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004348-27-IT   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002996-91-GB   Canada;Germany;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002996-91-DE   Canada;Germany;United Kingdom;United States;
Seladelpar 10 mg Capsule   
   CymaBay Therapeutics, Inc.
      2017   Phase 3   NCT03301506   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Seladelpar 10 mg or less   
   CymaBay Therapeutics, Inc.
      2021   Phase 1   NCT04950764   United States;
Seladelpar 5 mg Capsule   
   CymaBay Therapeutics, Inc.
      2017   Phase 3   NCT03301506   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Seladelpar 5-   
   CymaBay Therapeutics, Inc.
      2018   Phase 3   NCT03602560   Argentina;Australia;Austria;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Setanaxib   
   Genkyotex Suisse SA
      2021   Phase 2/Phase 3   NCT05014672   United States;
Sortis   
   Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology
      2005   -   EUCTR2005-002160-28-AT   Austria;
Sublimated mare milk   
   National Scientific Medical Center, Kazakhstan
      2018   -   NCT03665519   Kazakhstan;
TQA3526   
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2020   Phase 2   NCT04278820   China;
Tauroursodeoxycholic Acid Capsules   
   Beijing Friendship Hospital
      2009   Phase 3   NCT01857284   China;
Tetrathiomolybdate   
   George Brewer
      2006   Phase 3   NCT00805805   United States;
Thiamine   
   Henning Grønbæk
      2021   Phase 4   NCT04893993   Denmark;
Tiamin DAK   
   Aarhus University Hospital
      2021   Phase 2   EUCTR2020-004935-26-DK   Denmark;
Tiamin SAD   
   Aarhus University Hospital
      2021   Phase 2   EUCTR2020-004935-26-DK   Denmark;
Tigecycline   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2006   Phase 1   NCT00406237   Puerto Rico;United States;
Tropifexor   
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-001590-41-PL   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-001590-41-DE   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States;
Truvada and Kaletra   
   University of Alberta
      2012   -   NCT01614405   Canada;
UDCA   
   Beijing 302 Hospital
      2016   Phase 1/Phase 2   NCT02965911   China;
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2021   Phase 3   NCT04956328   China;
   Gunma Liver Study Group
      2003   -   JPRN-C000000225   Japan;
   Longhua Hospital ShangHai University of Traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000037244   China;
   Longhua Hospital, Shanghai University of Traditional Chinese Medicine
      2019   Phase 0   ChiCTR1900027043   China;
   Longhua Hospital, Shanghai University of traditional Chinese Medicine
      2019   Phase 0   ChiCTR1900026813   China;
   Peking Union Medical College Hosipital
      2018   -   ChiCTR1800020160   China;
   University of Leipzig
      2019   -   NCT04076527   Germany;
   Xiangya Hospital of Central South University
      2021   -   ChiCTR2100046346   China;
   Xijing Hospital of Digestive Diseases
      2016   Phase 3   NCT02916641   China;
      2016   Phase 3   NCT02916290   China;
      2016   Phase 3   NCT02823366   China;
      2016   Phase 3   NCT02823353   China;
UDCA (Ursodeoxycholic acid)   
   Dr. Falk Pharma GmbH
      2008   Phase 4   NCT01510860   Germany;
Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation   
   Vinmec Research Institute of Stem Cell and Gene Technology
      2019   Phase 1/Phase 2   NCT04522869   Vietnam;
Ursodeoxycholic Acid (URSO)   
   Intercept Pharmaceuticals
      2007   Phase 2   NCT00550862   Austria;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Ursodeoxycholic Acid 300mg capsule   
   University of Sao Paulo General Hospital
      2016   -   NCT03489889   Brazil;
Ursodeoxycholic Acid 300mg tablet   
   University of Sao Paulo General Hospital
      2016   -   NCT03489889   Brazil;
Ursodeoxycholic Acid Capsules   
   Beijing Friendship Hospital
      2009   Phase 3   NCT01857284   China;
Ursodeoxycholic acid   
   DR. FALK PHARMA GMBH
      2009   Phase 3   EUCTR2007-004040-70-IT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
   Dr. Falk Pharma GmbH
      2006   -   EUCTR2006-003712-22-DE   Germany;
   GlaxoSmithKline
      2014   Phase 2   NCT01899703   United Kingdom;
   Peking Union Medical College Hospital
      2020   Phase 4   NCT04650243   China;
   Robert Chunhua Zhao, MD, PhD
      2011   Phase 1   NCT01440309   China;
   Shanghai Municipal Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037243   China;
   The University Of Adelaide
      2020   Phase 3   EUCTR2018-004011-44-GB   Australia;Finland;Netherlands;Sweden;United Kingdom;
   The University of Adelaide
      2020   Phase 4   EUCTR2018-004011-44-FI   Australia;Finland;Netherlands;Sweden;United Kingdom;
   Xiangya Hospital of Central South University
      2021   -   ChiCTR2100046346   China;
Ursodeoxycholic acid combination of immunosuppressive agents   
   Xiaoli Fan
      2016   -   NCT02936596   China;
Ursodeoxycholic acid combined with total glucosides of paeony   
   West China Hospital
      2021   Phase 4   NCT04618575   China;
Ursodeoxycholic acid only   
   West China Hospital
      2021   Phase 4   NCT04618575   China;
Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)   
   West China Hospital
      2020   Phase 4   NCT04617561   China;
Ursodeoxycholsäure   
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria;
Ursodiol   
   National Center for Research Resources (NCRR)
      1994   Phase 3   NCT00004784   -
      1989   Phase 3   NCT00004748   -
Ursofalk   
   Dr. Falk Pharma GmbH
      2013   -   EUCTR2007-004040-70-PL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004040-70-GB   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2007-004040-70-DK   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2007-004040-70-AT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-004040-70-SE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-004040-70-ES   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-NL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-LT   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-HU   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-FR   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-FI   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004040-70-DE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom;
Ursofalk® 500 mg Filmtabletten   
   Dr. Falk Pharma GmbH
      2006   -   EUCTR2006-003712-22-DE   Germany;
Ursofalk® 500 mg film-coated tablets   
   Dr. Falk Pharma GmbH
      2008   -   EUCTR2008-001524-31-NL   Germany;Netherlands;
      2008   -   EUCTR2008-001524-31-DE   Germany;Netherlands;
Ursofalk® capsules   
   Dr. Falk Pharma GmbH
      2008   -   EUCTR2008-001524-31-NL   Germany;Netherlands;
      2008   -   EUCTR2008-001524-31-DE   Germany;Netherlands;
Ustekinumab   
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01389973   Canada;United States;
   Janssen-Cilag International N.V.
      2011   Phase 2   EUCTR2011-000554-31-GB   Canada;France;Germany;Italy;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000554-31-SE   Canada;France;Germany;Italy;Sweden;United Kingdom;United States;
Vitamin D   
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012489   Japan;
      2013   -   JPRN-UMIN000012193   Japan;
Volixibat   
   Mirum Pharmaceuticals, Inc.
      2021   Phase 2   NCT05050136   United States;
Zoledronic acid   
   Tokai University School of Medicine
      2018   -   JPRN-UMIN000031384   Japan;
[14C]-A4250 capsule   
   Albireo
      2017   Phase 1   NCT03082937   United Kingdom;
mesenchymal stem cell   
   Robert Chunhua Zhao, MD, PhD
      2011   Phase 1   NCT01440309   China;